Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;18(1):503-508.
doi: 10.3892/etm.2019.7598. Epub 2019 May 22.

Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice

Jinshui He  1 , Yueya Kang  1 , Chaowei Lian  1 , Jinzhi Wu  2 , Huowang Zhou  1 , Xiaoling Ye  1
Affiliations

Effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic mice

Jinshui He et al. Exp Ther Med. 2019 Jul.

Abstract

This study analyzed the effect of miR-19b on the protective effect of Exendin-4 on islet cells in non-obese diabetic (NOD) mice. Twenty-four NOD/LT mice were randomized, according to the random number table, into a control group (4 µg/kg•day), a low-dose group (2 µg/kg•day Exendin-4), a medium-dose group (4 µg/kg•day Exendin-4) and a high-dose group (8 µg/kg•day Exendin-4) (n=6), with miR-19b expression interfered (an interference group) except for the control group. RT-qPCR was used to detect interference results and different doses of Exendin-4 were given for 8 weeks of intervention after the interference. CD4+ and CD8+ cell levels were detected by flow cytometry, IL-2 and IL-10 levels in the peripheral blood by enzyme-linked immunosorbent assay, and the apoptosis rate of islet cells in the pancreatic tissue by TUNEL. After 4 and 8 weeks of Exendin-4 intervention, mice in the high-dose group had lower blood glucose level than the medium-dose group (P<0.05). The medium-dose group had lower CD4+ cell level than the high-dose group (P<0.05), while the medium-dose group had higher CD8+ cell level than the high-dose group (P<0.05). After 8 weeks of intervention, compared with the medium-dose group, the high-dose group had lower IL-2 level (P<0.05), but higher IL-10 level (P<0.05). After 8 weeks of intervention, the medium-dose group had a higher apoptosis rate than the high-dose group (P<0.05). In conclusion, the decrease in miR-19b expression can improve the therapeutic effect of Exendin-4 on NOD, control blood glucose effectively and improve inflammatory response and immune function, as well as reduce islet cell injury. The increase in the dose of Exendin-4 can further improve its therapeutic effect on NOD.

Keywords: Exendin-4; islet cells; miR-19b; non-obese diabetes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
miR-19b expression level in the peripheral blood of mice in the control and interference groups. *P<0.05.
Figure 2.
Figure 2.
Results of islet cell apoptosis rate detection. *P<0.05 compared with the control group at the same time-point; #P<0.05 compared with the low-dose group at the same time-point; &P<0.05 compared with the medium-dose group at the same time-point.
See this image and copyright information in PMC

References

    1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37(Suppl 1):S14–S80. doi: 10.2337/dc14-S014. - DOI - PubMed
    1. Pai LW, Hung CT, Li SF, Chen LL, Chung Y, Liu HL. Musculoskeletal pain in people with and without type 2 diabetes in Taiwan: A population-based, retrospective cohort study. BMC Musculoskelet Disord. 2015;16:364. doi: 10.1186/s12891-015-0819-4. - DOI - PMC - PubMed
    1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(Suppl 1):S62–S67. doi: 10.2337/dc09-S062. - DOI - PMC - PubMed
    1. Wang Z, York NW, Nichols CG, Remedi MS. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 2014;19:872–882. doi: 10.1016/j.cmet.2014.03.010. - DOI - PMC - PubMed
    1. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091. doi: 10.2337/diacare.28.5.1083. - DOI - PubMed